STLN: Starling Oncology Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
Alpha Vantage · Quantisnow · · AI-summarised by FinFlash
Starling Oncology Inc. (STLN) has filed an SEC Form 8-K, disclosing Regulation FD information, financial statements, and exhibits. This filing reaffirms the company's FY26 revenue guidance of $650-660M and Adjusted EBITDA of $4-6M, with 3Q26 EBITDA reported as positive at $3.4M. This news highlights the company's current financial performance and outlook.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.